ance of A␤40 over the much more amyloidogenic speThe rationale for this approach is that a reduction in A␤ cies of the peptide, A␤42. LRP also favors A␤40 over a more amyloidogenic, mutant form of A␤ containing two APP gene mutations (Dutch and Iowa) known to cause
(Yan et al., 2000)
. One of these ligands is A␤, for which RAGE has an affinity in the nanomolar range. This supports the possibility for an endogenous physiological interaction between A␤ and RAGE. Indeed, data from animal models have shown that downregulation of RAGE is able to inhibit the influx of A␤ from the periphery into the CNS (Deane et al., 2003) . It is also worth noting that the binding of A␤ to RAGE has been shown to stimulate cellular responses that are potentially pathological, including expression of proinflammatory cytokines and decreased cerebral blood flow (reviewed in Zlokovic, 2004).
Besides RAGE, gp330/megalin has also been reported to transport circulating plasma A␤ back into the brain, in a complex with apoJ (Zlokovic et al., 1996). However, since gp330/megalin would normally be saturated by abundant amounts of plasma apoJ under physiological Another recent study employing chronic transgenic overexpression of IDE (2-fold over endogeneous) in mice overexpressing human APP harboring both APP 717 and vascular amyloidosis. The latter findings suggest that APP 670/671 missense mutations revealed a 50% decrease these mutations may not only render A␤ more prone to in both soluble and insoluble A␤ X-40 and A␤ X-42 levels amyloid formation, but may also impede efflux out of (Leissring et al., 2003) . In addition, in the APP/IDE double the brain via LRP. These data also more generally imply transgenic mice, A␤ plaque burden was diminished by that fibrillogenic forms of A␤, which accumulate in AD 50% and there was a significant reduction in the rate brain, may be difficult to remove from the CNS via LRP.
of premature death as compared to age-matched APP Finally, the same study also shows that A␤ can promote transgenic littermates. Collectively, these findings serve the proteasome-dependent degradation of LRP. Based to validate a role for IDE in A␤ degradation in vivo and on this observation, the authors make the interesting suggest that even moderate increases in IDE activity speculation that this may perhaps explain previous obcan lead to dramatic changes in steady-state A␤ levels servations of relatively low LRP activity in brain microvesas well as overall amyloid plaque burden. Further supsels in AD patients and mutant APP mouse models of port for the role of IDE in AD pathogenesis stems from 
